Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.57 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 8/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | PIP5K1B | O14986 | 1/20 | 0.47 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PIP5K1A | Q99755 | 1/20 | 0.47 |
| ▸ | GALR2 | O43603 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1518723 | 0.86 | CNR1 (0.69) | CNR1MAPK8MAPK10MAPK14SMN1; SMN2 | |
| SCHEMBL1518840 | 0.85 | TP53 (0.65) | CNR1MAPK8MAPK10MAPTMEN1 | |
| SCHEMBL1518602 | 0.84 | MAPK10 (0.65) | CNR1MAPK8MAPK10KMT2AMAPK14 | |
| SCHEMBL1518862 | 0.83 | MEN1 (0.59) | CNR1MAPK8MAPK10MAPTMEN1 | |
| SCHEMBL1518686 | 0.82 | MAPK8 (0.59) | CNR1MAPK8MAPK10MAPTMEN1 | |
| SCHEMBL1518722 | 0.82 | CNR1 (0.64) | CNR1MAPK8MAPK10MAPTMAPK14 | |
| SCHEMBL1518936 | 0.81 | CNR1 (0.60) | CNR1MAPK8MAPK10MAPTMEN1 | |
| SCHEMBL5808224 | 0.81 | CNR1 (0.63) | CNR1MAPK8MAPK10MAPK14SMN1; SMN2 | |
| SCHEMBL1518769 | 0.80 | MAPK8 (0.59) | CNR1MAPK8MAPK10MAPTMEN1 | |
| SCHEMBL4124271 | 0.80 | RAB9A (0.64) | MAPTMEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2012-08-16 | — | — | US | disclosed |
| US-20060223807-A1 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL, A MASSACHUSETTS CORPORATION (US) | 2006-10-05 | — | — | US | disclosed |
| WO-2006104983-A1 | THERAPEUTIC METHODS FOR TYPE I DIABETES | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2004052880-A1 | PYRIDINE DERIVATIVES AS JNK INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | MAPK9, IAPP, RNASE1 | CNR1 4090/4885MAPK8 25/4885MAPK10 12/4885 |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | MAPK9, IAPP, RNASE1 | CNR1 4090/4885MAPK8 25/4885MAPK10 12/4885 |
| US-20060223807-A1 | Therapeutic methods for type I diabetes | MAPK9, IAPP, RNASE1 | CNR1 4090/4885MAPK8 25/4885MAPK10 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.